Business
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a cl...
About this update from Canadian Goldcamps Corp
[{"type":"text","content":"CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting\n\n\n\n\n Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression\n \n\n\n\n Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented\n \n\n\n CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three oral presentations at the upcoming 28\n \n th\n \n Annual Meeting of the American Society of Gene and Cell Therapy, taking place in New Orleans, LA, May 13 – 17, 2025.\n \n\n\n Details for the oral presentations are as follows:\n \n\n\n Title:\n \n Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of Urea Cycle Disorders\n \n\n Presenter: Dan Tardiff, Ph.D.\n \n Session title: Oligonucleotide Therapeutics II\n \n Session date and time: Friday May 16, 2025, 3:45 PM - 5:40 PM CT\n \n\n Title:\n \n Targeting Regulatory RNAs with Antisense Oligonucleotides for the Potential Treatment of SYNGAP1-Related Disorders\n \n\n Presenter: Dan Tardiff, Ph.D.\n \n Session title: Oligonucleotide Therapeutics II\n \n Session date and time: May 16, 2025, 3:45 PM - 5:40 PM CT\n \n\n Title:\n \n A First-in-Human Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study (SAD, MAD) in Healthy Volunteers to Evaluate the Safety and Tolerability of an Investigational Antisense Oligonucleotide Therapy (CMP-CPS-001) for the Treatment of Urea Cycle Diseases (UCDs): Interim Safety Readout\n \n\n Presenter: Yuri Maricich, M.D.\n \n Session title: Oligonucleotide Therapeutics II\n \n Session date and time: May 16, 2025, 3:45 PM - 5:40 PM CT\n \n\n The presentations will be made available on the CAMP4 website at\n \n https://investors.camp4tx.com/news-events/presentations\n \n simultaneously with ...